The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the <scp>United States</scp> medicare database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database

Published:2022-04-06 Issue:6 Volume:31 Page:643-651
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Johannes Catherine B.¹^ORCID,Saltus Catherine W.¹^ORCID,Kaye James A.¹^ORCID,Calingaert Brian²^ORCID,Kaplan Sigal³^ORCID,Gordon Mark Forrest⁴^ORCID,Andrews Elizabeth B.²^ORCID

Affiliation:

1. Department of Epidemiology RTI Health Solutions Waltham Massachusetts USA

2. Department of Epidemiology RTI Health Solutions Research Triangle Park North Carolina USA

3. Global Patient Safety & Pharmacovigilance Teva Pharmaceutical Industries Ltd. Netanya Israel

4. Global Specialty R&D Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA

Funder

Teva Pharmaceutical Industries

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5422

Reference30 articles.

1. Parkinson's disease

2. Epidemiology of Parkinson's disease

3. Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity

4. Antiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson’s Disease

5. Pharmacological Treatment of Parkinson Disease

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanin—The Éminence Grise of Melanoma and Parkinson’s Disease Development;Cancers;2023-11-23

2. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system;Scientific Reports;2023-11-06

3. Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson’s Disease, Necessary Again?;Cells;2022-12-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3